Andrew Combs

CIK: 0001825005

Transaction Breakdown

Open Market Buys (P)3 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PRLD

Prelude Therapeutics Inc

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

PRLD
Prelude Therapeutics Inc
Feb 4, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
230K shares-
PRLD
Prelude Therapeutics Inc
Mar 25, 2025
Purchase(P)
Direct
100K shares at avg. $0.69$69K
PRLD
Prelude Therapeutics Inc
Feb 4, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
175K shares-
PRLD
Prelude Therapeutics Inc
Dec 23, 2024
Purchase(P)
Direct
60K shares at avg. $1.37$82K
PRLD
Prelude Therapeutics Inc
Dec 20, 2024
Purchase(P)
Direct
3.1K shares at avg. $1.15$4K

		Type	Shares	Price		Ownership
Feb 4, 2026	PRLD Prelude Therapeutics Inc	Award(A) Employee Stock Option (right to buy)	230,000	-	-	Direct
Mar 25, 2025	PRLD Prelude Therapeutics Inc	Purchase(P)	100,000	$0.69	$69,250	Direct
Feb 4, 2025	PRLD Prelude Therapeutics Inc	Award(A) Employee Stock Option (right to buy)	175,000	-	-	Direct
Dec 23, 2024	PRLD Prelude Therapeutics Inc	Purchase(P)	60,000	$1.37	$82,002	Direct
Dec 20, 2024	PRLD Prelude Therapeutics Inc	Purchase(P)	3,075	$1.15	$3,536	Direct

1-5 of 5 transactions

About Combs Andrew

Combs Andrew (SEC CIK 0001825005) files insider reports with the SEC as Chief Chemistry Officer of Prelude Therapeutics Inc (PRLD).

Signal8 holds 4 ownership filings by Combs Andrew, all Form 4s, filed between Dec 26, 2024 and Feb 5, 2026. Those filings report 5 transactions, from Dec 20, 2024 to Feb 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Combs Andrew's filings is in WILMINGTON, DE.

Recent filings by Combs Andrew

Feb 4, 2026: Grant or award of PRLD derivative securities (Form 4, code A).
Mar 25, 2025: Open-market purchase of PRLD shares (Form 4, code P).
Feb 4, 2025: Grant or award of PRLD derivative securities (Form 4, code A).
Dec 23, 2024: Open-market purchase of PRLD shares (Form 4, code P).
Dec 20, 2024: Open-market purchase of PRLD shares (Form 4, code P).

Other insiders filing for Prelude Therapeutics Inc (PRLD)

BAKER BROS. ADVISORS LP, Director
Dorton Katina, Director
Babler Martin, Director
Bonita David P, Director
Sandor Victor, Director
FRIEDMAN PAUL A, Director

How to read Form 4 transaction codes